AEPODIA
Aepodia’s history starts in 2007. Spin-out of a top 10 US Pharma Company, Aepodia was created by a group of experts in early-phase clinical development. Since its creation, Aepodia has confirmed its reputation by designing, preparing and conducting more than 90 Projects in healthy volunteers or patients with a strong focus on client’s needs and results outcomes. Aepodia has established solid and effective collaborations with pharmaceutical companies over the world (EU, US, Japan), as well as with biotech companies in Europe.
AEPODIA
Social Links:
Industry:
Biotechnology Consulting Legal Life Science Pharmaceutical
Founded:
2007-01-01
Address:
Louvain-la-neuve, Vlaams-Brabant, Belgium
Country:
Belgium
Website Url:
http://www.aepodia.com
Total Employee:
11+
Status:
Active
Contact:
+32010392011
Email Addresses:
[email protected]
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Tag Manager Google Analytics Global Site Tag Google Universal Analytics Google Analytics 4 Nginx US Privacy User Signal Mechanism
Similar Organizations
Anglia DNA
Anglia DNA is an independent laboratory offering scientific services for DNA, drug, and alcohol testing.
Drugabilis
Drugabilis specializes in solid form characterisation and formulation development for human and animal health.
Future Care Capital
FCC is committed to engaging, educating and involving all generations in the development and delivery of unified health and care provision.
Marcus & Associates | Life Sciences Executive Search Experts
Marcus & Associates is a leading life sciences executive search firm helping clients acquire the industry's'​ most talented individuals.
Tecrea
Tecrea is the provider world leading cell and tissue delivery technology for research and drug development applications.
The Research Network
The Research Network is a Pharmaceutical R&D Scientific Consultancy, Project Management, Outsourcing, Training And Due Diligence Services.
Current Employees Featured
Founder
Newest Events participated
Participated in Partnerships in Clinical Trials Europe 2017
on 2017-11-28 as exhibitor
Official Site Inspections
http://www.aepodia.com
- Host name: 149.13.127.10
- IP address: 149.13.127.10
- Location: Clichy France
- Latitude: 48.9012
- Longitude: 2.3072
- Timezone: Europe/Paris
- Postal: 92110
More informations about "Aepodia"
Acepodia - Crunchbase Company Profile & Funding
Acepodia is a clinical-stage biotechnology business that is using its proprietary Antibody-Cell Conjugation (ACC) platform technology to produce first-in-class cell treatments to solve gaps in cancer care. Acepodia employs this live-cell …See details»
Leadership-Acepodia | POWERFUL, ACCESSIBLE CELL THERAPIES …
Jennifer has more than 25 years of Quality and CMC experience for CAR-T cell therapy, Antibody therapeutics, and Antibody Drug Conjugates. Jennifer is now the VP of Quality at Acepodia …See details»
Acepodia is pioneering next-generation cell therapy.
Acepodia was spun-off from Professor Carolyn Bertozzi 's lab who won the 2022 Nobel Prize for Chemistry and founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, …See details»
Acepodia - LinkedIn
Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients.See details»
Acepodia Information - RocketReach
Acepodia is a clinical-stage biotechnology company developing innovative and highly effective cell therapies for cancer that are broadly accessible for patients. Leveraging its Antibody-Cell …See details»
Member Profile - TRPMA Official Website
Jun 19, 2017 Acepodia was founded in 2017 by Dr. Patrick Y. Yang, former EVP of Juno Therapeutics, Roche, and Genentech, and by Dr. Sonny Hsiao, UC Berkeley Cell Biologist …See details»
Acepodia Company Profile - Office Locations, Competitors ... - Craft
Acepodia Announces FDA Clearance of IND Application for ACE1831, an Anti-CD20 Armed Allogeneic gamma delta T-cell Therapy Candidate to Treat Patients with non-Hodgkin's …See details»
Acepodia: Contact Details, Revenue, Funding, Employees and …
Acepodia is a clinical-stage biotechnology company developing accessible cancer cell therapies using its Antibody-Cell Conjugation (ACC) technology. By linking tumor-targeting antibodies to …See details»
Acepodia Company Profile 2024: Stock Performance & Earnings
Acepodia has 48 total employees. What industry is Acepodia in? Acepodia’s primary industry is Drug Discovery. Is Acepodia a private or public company? Acepodia is a Public company. …See details»
Acepodia, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Acepodia is composed of seasoned leaders and scientific experts dedicated to advancing its robust pipeline of ACE therapies with the potential to bring innovative, effective, and affordable …See details»
Company Organization-Acepodia | POWERFUL, ACCESSIBLE CELL …
We sincerely thank you for your support to Acepodia. Personal Investment and Stock Affairs Agent Information PHONE: +886-2-xxxxxxxx. ADDRESS: xxxxxxxxxxx. Professional …See details»
Acepodia, Pfizer click together for chemistry-based cell therapy
Sep 3, 2024 The chemistry-inclined company’s lead asset is ACE1831, a cell therapy for non-Hodgkin lymphoma currently in phase 1 trials. ACE1831 T cells target CD20, a protein …See details»
Acepodia - Overview, News & Similar companies | ZoomInfo.com
View Acepodia (www.acepodia.com) location in California, United States , revenue, industry and description. Find related and similar companies as well as employees by title and much more. …See details»
Acepodia snags $109M—and an early Zoom backer—to ... - Fierce …
Dec 2, 2021 Elsewhere in the C-suite, Acepodia has gone on a hiring spree since disclosing a $47 million series B in March. AbbVie cancer R&D veteran Thorsten Graef, M.D., Ph.D., joined …See details»
Acepodia Biotech, Inc. - Drug pipelines, Patents, Clinical trials
ACE1831 is a potential antibody‑armed allogeneic gamma delta T cell therapy developed using Acepodia's unique antibody-cell conjugation (ACC) technology as an optimized T cell engager …See details»
Acepodia Announces 2025 Clinical Development Milestones and ...
Acepodia (The Company, 6976.TT) announced today at the investor conference the clinical trial progress for its core product candidates ACE1831 and ACE2016, along with a detailed …See details»
Acepodia Raises $109 Million Series C Financing to Advance …
Acepodia is developing a first-in-class pipeline of ACE therapies that use its ACC technology to link tumor-targeting antibodies to immune cells, such as natural killer (NK) cells or gamma …See details»
Acepodia picks up strong hand for cell therapies in $100M raise
Jun 6, 2023 Acepodia is ready to ante up its bet on cell therapy after turning over a brand new $100 million series D financing that will support the biotech's pipeline of medicines for solid …See details»
Acepodia Secures $100 Million Series D Financing to Advance First …
Jun 6, 2023 Acepodia is a clinical-stage biotechnology company developing first-in-class cell therapies with its unique Antibody-Cell Conjugation (ACC) platform technology to address …See details»